Skip to main content

New Risk Score Predicts Mortality for Atrial Fibrillation Patients Undergoing Transcatheter Aortic Valve Replacement


Mount Sinai researchers develop new risk stratification tool to optimize patient care and outcomes after TAVR

A large-scale international study led by Mount Sinai has yielded the first risk score that can help predict mortality for patients with atrial fibrillation (AFib) who have undergone a successful transcatheter aortic valve replacement (TAVR) and discharged home.

The results from the study, known as the ENVISAGE-TAVI AF trial and the largest of its kind, could lead to improved management of care and outcomes for this patient population. They were announced Sunday, August 28, as a late-breaking clinical trial at the European Society of Cardiology Congress (ESC Congress 2022).

Learn More